RNS Number : 8278M
Lloyds Bank PLC
19 November 2024
 

 

19 November 2024

Publication of Supplementary Prospectus

The following Supplementary Prospectus has been approved by the Financial Conduct Authority and is available for viewing:

Supplementary Prospectus dated 19 November 2024 (the "Supplementary Prospectus") relating to the £35,000,000,000 Euro Medium Term Note Programme of Lloyds Bank plc.

The Supplementary Prospectus should be read and construed in conjunction with the prospectus dated 28 March 2024, as supplemented by the supplementary prospectuses dated 24 April 2024, 25 July 2024 and 23 October 2024, relating to the above programme (the "Prospectus").

To view the Supplementary Prospectus, please paste the following URL into the address bar of your browser:

http://www.rns-pdf.londonstockexchange.com/rns/8278M_1-2024-11-19.pdf 

The Supplementary Prospectus has been submitted to the National Storage Mechanism and will shortly be available for inspection at: https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

For further information, please contact:

Investor Relations:

Douglas Radcliffe

Group Investor Relations Director

Tel:                  +44 (0) 20 7356 1571

Email:              douglas.radcliffe@lloydsbanking.com

 

Group Corporate Treasury:
Kristofer Middleton
Head of Term Issuance and Capital Structuring

Tel:                  +44 (0) 207 356 1122

Email:              Kristofer.Middleton@lloydsbanking.com

 

Group Corporate Affairs:

Matt Smith

Head of Media Relations

Tel:                  +44 (0) 7788 352 487

Email:              matt.smith@lloydsbanking.com

Lloyds Bank plc

25 Gresham Street,

London EC2V 7HN

United Kingdom

 

DISCLAIMER - INTENDED ADDRESSEES

Please note that the information contained in this announcement and the Supplementary Prospectus may be addressed to and/or targeted at persons who are residents of particular countries (specified in the Prospectus) only and is not intended for use and should not be relied upon by any person outside these countries and/or to whom this announcement and the Supplementary Prospectus are not addressed. Prior to relying on the information contained in this announcement and the Supplementary Prospectus, you must ascertain from the Prospectus whether or not you are one of the intended addressees of the information contained in this announcement and the Supplementary Prospectus.

In particular, this announcement and the Supplementary Prospectus do not constitute an offer or invitation to subscribe for, or purchase securities in the United States or in any other jurisdiction where such an offer or invitation would be unlawful. This announcement and the Supplementary Prospectus are not for distribution in the United States. The securities described herein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), or under any relevant securities laws of any state of the United States of America and are subject to U.S. tax law requirements. Subject to certain exceptions, the securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons or to persons within the United States of America, as such terms are defined in Regulation S under the Securities Act. There will be no public offering of the securities in the United States.

Your right to access this service is conditional upon complying with the above requirement.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
PSPFLFIFLILALIS